Investment
Features
FeesSafety
Academy
More
Pluang+

GLDY Class B shares now custody-eligible via Inspira Financial, expanding gold exposure for traditional investors.

Market News
21 Jul 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Streamex Corp. announced that its GLDY Class B shares, a gold-backed, yield-bearing asset, are now available for custody through Inspira Financial, a major qualified custodian managing over $63 billion in assets. This development allows institutional investors, wealth managers, and advisors to access GLDY within their existing custody frameworks, significantly broadening GLDY's reach into traditional finance markets. GLDY Class B shares maintain the same benefits as the tokenized version and can be converted into tokens anytime, providing flexibility and liquidity. This partnership is part of Streamex's strategy to increase GLDY's adoption by integrating with established financial infrastructure.

More News

Packaging Corp of America Q2 2026 revenue forecast rises 10.7%, EPS expected to drop 6.9%.

Packaging Corp of America Q2 2026 revenue forecast rises 10.7%, EPS expected to drop 6.9%.

Packaging Corporation of America is set to release its Q2 2026 earnings on July 22, with analysts expecting revenue of $2.40 billion, a 10.7% increase from last year, driven by higher packaging volume and pricing. However, earnings per share are fore...

Company Fundamentals
Neutral
43 minutes ago
Global automotive pumps market to reach $34.15B by 2035 with 1% CAGR, led by passenger cars and engine/HVAC applications.

Global automotive pumps market to reach $34.15B by 2035 with 1% CAGR, led by passenger cars and engine/HVAC applications.

The global automotive pumps market is projected to grow from $31.11 billion in 2026 to $34.15 billion by 2035, at a CAGR of 1.0%. Growth is driven by increased pump content in passenger cars, especially for engine and HVAC systems, as OEMs adopt adva...

Market News
Bullish
43 minutes ago
Celldex cuts price target after halting Phase 2 trial for key drug due to efficacy failure.

Celldex cuts price target after halting Phase 2 trial for key drug due to efficacy failure.

Celldex Therapeutics lowered its price target from $67 to $61 after stopping its Phase 2 trial for barzolvolimab, a drug for prurigo nodularis, because it failed to meet primary efficacy goals. Despite this setback, the drug showed a strong safety pr...

Analyst Insights
Bearish
1 hour ago
Equinor Q2 2026 revenue beats estimates despite EPS miss, declares dividend and continues buyback.

Equinor Q2 2026 revenue beats estimates despite EPS miss, declares dividend and continues buyback.

Equinor reported mixed Q2 2026 results with earnings per share of $1.33, slightly below analyst expectations of $1.38. However, revenue rose to $34.40 billion, surpassing forecasts due to a 3% production increase and higher energy prices. The company...

Company Fundamentals
Neutral
1 hour ago
Knight-Swift forecasts Q2 EPS of $0.51 and $2.05B revenue amid rising freight demand.

Knight-Swift forecasts Q2 EPS of $0.51 and $2.05B revenue amid rising freight demand.

Knight-Swift Transportation Holdings is set to report its Q2 earnings on July 22, 2026, with analysts expecting an EPS of $0.51 and revenue of $2.05 billion, reflecting an 8% revenue increase year-over-year. The company benefits from improving freigh...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App